Rikoon Group’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q1
Sell
-4,889
Closed -$285K 236
2020
Q4
$285K Sell
4,889
-122
-2% -$7.36K 0.08% 192
2020
Q3
$317K Buy
5,011
+1
+0% +$69 0.1% 161
2020
Q2
$385K Sell
5,010
-314
-6% -$24.1K 0.13% 138
2020
Q1
$398K Sell
5,324
-479
-8% -$33.1K 0.16% 121
2019
Q4
$377K Sell
5,803
-1,399
-19% -$91.1K 0.13% 143
2019
Q3
$456K Sell
7,202
-299
-4% -$19.5K 0.17% 126
2019
Q2
$507K Sell
7,501
-299
-4% -$19.7K 0.19% 114
2019
Q1
$507K Buy
7,800
+1
+0% +$66 0.19% 117
2018
Q4
$488K Sell
7,799
-998
-11% -$69.8K 0.2% 114
2018
Q3
$679K Sell
8,797
-650
-7% -$49.1K 0.24% 100
2018
Q2
$669K Sell
9,447
-2,268
-19% -$160K 0.26% 93
2018
Q1
$856K Sell
11,715
-461
-4% -$36.6K 0.35% 81
2017
Q4
$872K Sell
12,176
-3,744
-24% -$284K 0.36% 78
2017
Q3
$1.29M Buy
15,920
+12,670
+390% +$969K 0.56% 48
2017
Q2
$230K Sell
3,250
-1,275
-28% -$84.8K 0.1% 154
2017
Q1
$310K Sell
4,525
-478
-10% -$33.6K 0.14% 135
2016
Q4
$332K Sell
5,003
-1,554
-24% -$116K 0.15% 133
2016
Q3
$518K Buy
+6,557
New +$533K 0.41% 70

Other funds holding GILD

Rikoon Group's GILD Position: Q1 2021 in Review

Rikoon Group sold out of Gilead Sciences (GILD) in Q1 2021, closing a stake of 4,889 shares — an estimated $285K sold.

Rikoon Group first reported a position in GILD in Q3 2016 and held it in 18 quarters. The position peaked at $1.29M in Q3 2017. 1,568 funds tracked by Wall St. Rank hold GILD as of Q1 2021.

  • Rikoon Group reported no remaining Gilead Sciences position as of Q1 2021 after selling out during the quarter.
  • Rikoon Group sold 4,889 Gilead Sciences shares in Q1 2021, an estimated $285K.
  • Rikoon Group first reported a position in Gilead Sciences in Q3 2016 and held it in 18 quarters.
  • Rikoon Group's Gilead Sciences position peaked at $1.29M in Q3 2017.
  • 1,568 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2021.

Based on Rikoon Group's 13F filing for Q1 2021, filed 14 May 2021.